LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Theravance Biopharma Inc

Open

11.35 5.19

Overview

Share price change

24h

Current

Min

10.67

Max

11.43

Key metrics

By Trading Economics

Income

1.9M

-14M

Sales

-3.4M

15M

EPS

-0.173

Profit margin

-88.244

Employees

97

EBITDA

-7.5M

-14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+57.85% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

118M

558M

Previous open

6.16

Previous close

11.35

Technical Score

By Trading Central

Confidence

Bullish Evidence

Theravance Biopharma Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2025, 10:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

2 Jun 2025, 10:00 UTC

Acquisitions, Mergers, Takeovers

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

Peer Comparison

Price change

Theravance Biopharma Inc Forecast

Price Target

By TipRanks

57.85% upside

12 Months Forecast

Average 17 USD  57.85%

High 24 USD

Low 12 USD

Based on 4 Wall Street analysts offering 12 month price targets forTheravance Biopharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

9.77 / 10.39Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.